PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.05
D/E ratio less than half the Medical - Pharmaceuticals median of 0.14. Benjamin Graham would praise this conservative approach, but check if excess equity dilutes returns.
-2.18
Net cash position versus Medical - Pharmaceuticals median net debt of 1.03. Peter Lynch would praise the flexibility but check if overcapitalized versus growth opportunities.
658.25
Coverage of 658.25 versus zero Medical - Pharmaceuticals median interest expense. Walter Schloss would verify if our leverage provides advantages.
0.71
Current ratio below 50% of Medical - Pharmaceuticals median of 2.91. Michael Burry would check for immediate refinancing needs.
0.12%
Intangibles less than half the Medical - Pharmaceuticals median of 3.46%. Warren Buffett would verify if this conservative approach misses valuable brand-building opportunities.